Concepedia

Author

Nicolas Moosmann

Ludwig-Maximilians-Universität München

Also Known As

N Moosmann, N. Moosmann, Nicolas Moosmann, Wolfgang Bank

79

Publications

1.2K

Citations

14

H-Index

20

Concepts

All Affiliations

Ludwig-Maximilians-Universität MünchenKrankenhaus Barmherzige BrüderPraxis für Hämatologie und OnkologieLMU KlinikumKlinikum St. Marien Amberg
NM

About

Nicolas Moosmann is an author at Ludwig-Maximilians-Universität München specializing in radiation oncology, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

149

2

Health Sciences

3

3

138

3

Pathology

3

3

41

4

Gastroenterology

1

1

108

5

Immunology

1

1

16

Nicolas Moosmann

×

15

Publications

662

Citations

12

H-Index

YearCitations

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling‐Kaiser,

Journal of Clinical Oncology

2011

116

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Beate Rau, Hauke Lang, Alfred Koenigsrainer,

Journal of Clinical Oncology

2023

113

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

Rainer Fietkau, Michael Ghadimi, Robert Grützmann,

Journal of Clinical Oncology

2022

108

Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group

Sebastian Stintzing, Christine Kapaun, Rüdiger P. Laubender,

International Journal of Cancer

2012

80

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

Stefan Boeck, Ralf Wilkowski, Christiane J. Bruns,

Oncology

2007

55

The influence of <i>KRAS</i> and <i>BRAF</i> mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

Dominik Paul Modest, Andreas Jung, Nicolas Moosmann,

International Journal of Cancer

2011

49

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

Sebastian Stintzing, Ludwig Fischer von Weikersthal, Ursula Vehling‐Kaiser,

British Journal of Cancer

2011

28

Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Arndt Stahler, Sebastian Stintzing, Dominik Paul Modest,

Clinical Cancer Research

2020

24

Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).

Nicolas Moosmann, Ludwig Fischer von Weikersthal, U. Vehling-Kaiser,

Journal of Clinical Oncology

2010

16

Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group

Volker Heinemann, Ludwig Fischer von Weikersthal, U. Vehling-Kaiser,

Journal of Clinical Oncology

2008

14

Page 1